Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Received Date † | September 11, 2005 | ||||||||
Last Updated Date | January 9, 2007 | ||||||||
Start Date † | |||||||||
Current Primary Outcome Measures † |
|
||||||||
Original Primary Outcome Measures † |
Determine the feasibility and safety of intradermal adminisration of the ImMucin peptide combined with GM-CSF for maximal stimulation of the draining lymphnodes. | ||||||||
Change History | Complete list of historical versions of study NCT00162500 on ClinicalTrials.gov Archive Site | ||||||||
Current Secondary Outcome Measures † |
|
||||||||
Original Secondary Outcome Measures † |
Document development of immune response to the peptide by in-vivo DTH and in-vitro assays and whenever possible, cytotoxic responses mediated by CD8 against HLA identical tumor. | ||||||||
Descriptive Information | |||||||||
Brief Title † | A Novel Vaccine for the Treatment of MUC1-Expressing Tumor Malignancies | ||||||||
Official Title † | A Novel Vaccine for the Treatment of MUC1-Expressing Tumor Malignancies | ||||||||
Brief Summary | Rationale: ImMucin was shown to be able to induce a robust cellular immune response mediated via both CD4+ and CD8+ T lymphocytes and therefore, could potentially be more effective in the majority of the target population. Purpose: The purpose of this study is to evaluate the safety and initial efficacy of ImMucin, a novel peptide vaccine in metastatic tumors expressing the MUC-1 Tumor Associated Antigen (TAA). |
||||||||
Detailed Description | |||||||||
Study Phase | Phase II | ||||||||
Study Type † | Interventional | ||||||||
Study Design † | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment | ||||||||
Condition † |
|
||||||||
Intervention † | Biological: Peptide Vaccine (MUC-1) | ||||||||
Study Arms / Comparison Groups | |||||||||
Publications * | |||||||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status † | Not yet recruiting | ||||||||
Enrollment † | 15 | ||||||||
Completion Date | |||||||||
Primary Completion Date | |||||||||
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Gender | Both | ||||||||
Ages | 18 Years and older | ||||||||
Accepts Healthy Volunteers | No | ||||||||
Contacts †† |
|
||||||||
Location Countries † | Israel | ||||||||
Expanded Access Status | |||||||||
Administrative Information | |||||||||
NCT ID † | NCT00162500 | ||||||||
Responsible Party | |||||||||
Secondary IDs †† | |||||||||
Study Sponsor † | Hadassah Medical Organization | ||||||||
Collaborators †† | Vaxil Therapeutics Ltd. | ||||||||
Investigators † |
|
||||||||
Information Provided By | Hadassah Medical Organization | ||||||||
Verification Date | September 2005 | ||||||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |